Skip to main
  1. Stocks
  2. Eikon Therapeutics Inc
  3. Forecast
EIKN

EIKN Stock Forecast & Price Target

EIKN Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 0%
Sell 17%
Strong Sell 0%

Bulls say

Eikon Therapeutics is compelling because its proprietary single-molecule tracking platform creates a differentiated discovery engine that measures real-time target engagement in living cells, potentially improving compound selection and reducing late-stage failure risk across target classes. The near-term thesis is strengthened by in-licensed clinical assets: EIK1001 posted a 63.1% pooled ORR and 90.8% DCR in TeLuRide-005 with no Grade ≥3 CRS across 72 patients, while EIK1003 showed 90.4% relative dose intensity with paclitaxel, supporting the idea that selectivity can unlock combinations previously limited by myelosuppression. Longer term, the wholly owned EIK1005 and EIK1006 programs add unencumbered upside, and the balance sheet funds operations into 2H27, giving the company time to convert multiple upcoming readouts into value.

Bears say

Eikon Therapeutics is viewed negatively because its value depends on a clinical pipeline that remains unvalidated, with no approved products and heavy reliance on exploratory single-arm data that may not hold up in registrational studies. Its lead programs face meaningful differentiation and class-risk hurdles: EIK1001 must outperform a moving pembrolizumab-based standard of care, while EIK1003, EIK1004, and EIK1005 enter crowded spaces with signals such as modest response rates, tachycardia, and uncertainty around durability and combination benefit. Financially, the company had $531.2 million in cash and marketable securities at June 30, 2026, but guided runway only into the 2H27, leaving it exposed to dilution and milestone obligations of up to $749 million and $956 million.

EIKN has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eikon Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

EIKN Analyst Forecast & Price Prediction

Get the latest EIKN stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in EIKN

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eikon Therapeutics Inc (EIKN) Forecast

Analysts have given EIKN a Buy based on their latest research and market trends.

According to 6 analysts, EIKN has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eikon Therapeutics Inc (EIKN)


EIKN Analyst Forecast & Price Prediction

Get the latest EIKN stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in EIKN

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover EIKN stock data and trends